284 related articles for article (PubMed ID: 7140021)
1. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.
Kirch W; Köhler H; Berggren G; Braun W
Clin Nephrol; 1982 Aug; 18(2):88-94. PubMed ID: 7140021
[TBL] [Abstract][Full Text] [Related]
2. Plasma and urine concentrations of acebutolol and its acetyl metabolite in patients with renal functional impairment.
Munn S; Bailey RR; Begg E; Ebert R; Ferry DG
N Z Med J; 1980 Apr; 91(658):289-91. PubMed ID: 6930006
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of nimodipine in normal and impaired renal function.
Kirch W; Rämsch KD; Dührsen U; Ohnhaus EE
Int J Clin Pharmacol Res; 1984; 4(5):381-4. PubMed ID: 6519852
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetics of acebutolol].
Collins RF
Nouv Presse Med; 1975 Dec; 4(46 Suppl):3223-8. PubMed ID: 768905
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A
Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of fleroxacin in renal impairment.
Weidekamm E
Am J Med; 1993 Mar; 94(3A):70S-74S. PubMed ID: 8452185
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol.
Flouvat B; Roux A; Chau NP; Viallet M; Andre-Fouet X; Woehrle R; Gregoire J
Eur J Clin Pharmacol; 1981 Mar; 19(4):287-92. PubMed ID: 7286031
[TBL] [Abstract][Full Text] [Related]
8. [Changes in renal function in the hours following an intravenous injection of acebutolol].
Pozet N; Zech P; Pellet M; Traeger J
Nouv Presse Med; 1975 Dec; 4(46 Suppl):3252-5. PubMed ID: 1219633
[TBL] [Abstract][Full Text] [Related]
9. The influence of renal function on the elimination kinetics of sulbenicillin in man.
Montanari A; Borghi L; Canali M; Coruzzi P; Novarini A; Borghetti A
Int J Clin Pharmacol Ther Toxicol; 1980; 18(5):225-8. PubMed ID: 7390672
[TBL] [Abstract][Full Text] [Related]
10. A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects.
Roux A; Henry JF; Fouache Y; Chau NP; Hervy MP; Forette F; Bourdarias JP; Flouvat B
Gerontology; 1983; 29(3):202-8. PubMed ID: 6852547
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics of acebutolol in man, following the oral administration of acebutolol HCl as a single dose (400 mg), and during and after repeated oral dosing (400 mg, b.d.).
Gulaid AA; James IM; Kaye CM; Lewellen OR; Roberts E; Sankey M; Smith J; Templeton R; Thomas RJ
Biopharm Drug Dispos; 1981; 2(2):103-14. PubMed ID: 7248475
[TBL] [Abstract][Full Text] [Related]
12. Observations on the pharmacokinetics of acebutolol.
Kaye CM; Kumana CR; Leighton M; Hamer J; Turner P
Clin Pharmacol Ther; 1976 Apr; 19(4):416-20. PubMed ID: 1269192
[TBL] [Abstract][Full Text] [Related]
13. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
[TBL] [Abstract][Full Text] [Related]
14. [Study of acebutolol dialysis and pharmacokinetic data in patients with renal insufficiency undergoing hemodialysis].
Roux A; Aubert P; Guédon J; Flouvat B
Nouv Presse Med; 1975 Dec; 4(46 Suppl):3228-33. PubMed ID: 1219629
[TBL] [Abstract][Full Text] [Related]
15. Acebutolol pharmacokinetics in renal failure.
Smith RS; Warren DJ; Renwick AG; George CF
Br J Clin Pharmacol; 1983 Sep; 16(3):253-8. PubMed ID: 6626416
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of ceftazidime in normal and impaired renal function.
Höffler D; Koeppe P; Williams KJ
Arzneimittelforschung; 1984; 34(1):72-6. PubMed ID: 6367755
[TBL] [Abstract][Full Text] [Related]
17. On the pharmacokinetics of latamoxef in normal and impaired renal function.
Höffler D; Koeppe P; Moecke D
Arzneimittelforschung; 1984; 34(3):317-20. PubMed ID: 6539614
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function.
Phillips M; Smith W; Balan G; Ward S
J Clin Pharmacol; 2008 Mar; 48(3):279-84. PubMed ID: 18192538
[TBL] [Abstract][Full Text] [Related]
19. Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine.
Jerling M; Abdallah H
Clin Pharmacol Ther; 2005 Sep; 78(3):288-97. PubMed ID: 16153399
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of indoprofen in patients with renal insufficiency (a preliminary report).
Wibell L; Nilsson P; Lindström B
Eur J Rheumatol Inflamm; 1981; 4(1):16-21. PubMed ID: 7341276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
